ImmunoScape

Singapore, Singapore · Founded 2016 · Privately Held (backing)

Developer of an immune profiling system and analytical tools designed to support immunotherapy clinical development. ImmunoScape is based in Singapore, Singapore and was founded in 2016. Its last reported valuation was $80.8 million in Jun 2025. It has raised $60.4 million.

Last reported valuation
$80.8M
Oct 2026
Priced at
—
Total raised
$60.4M
Last round
—

Who backs ImmunoScape?

9 investors
InvestorType
EDBIVenture capital
Johnson & Johnson Innovation - JLABSOther
The University of Tokyo Edge CapitalOther
Leonardo DiCaprioHigh net worth
Accelerate Technologies—
Amgen Ventures—
Anzu Partners—
NPR Holdings—
ScaleReady—
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

ImmunoScape investors

9 investors are on record for ImmunoScape, including EDBI, Johnson & Johnson Innovation - JLABS, The University of Tokyo Edge Capital and Leonardo DiCaprio.

Free account
More of ImmunoScape with a free account
  • ·Watch ImmunoScape: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 9 firms already write checks for companies like ImmunoScape. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View